Drugs / NSI-189
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01520649 | May 2012 → Feb 2014 | depressive disorder | Neuralstem Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01310881 | Feb → Nov 2011 | depressive disorder | Neuralstem Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02695472 | Mar 2016 → Jun 2017 | major depressive disorder | Neuralstem Inc. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-10-22 | Palisade Bio | Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders palisadebio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NSI-189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01520649 ↗ |
| Known as | NSI-189 PHOSPHATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4302505 ↗ |
| Modality | Small molecule | “NSI-189, a small molecule with neurogenic properties” PMID 28181668 ↗ Apr 2017 |
| Route | Oral | “Once daily oral administration” NCT01310881 ↗ |